Kraig Biocraft Laboratories Completes Installation of Automated Production Equipment

Kraig Labs bring new automated processing equipment to expedite silk processing  

ANN ARBOR, Mich., – June 23, 2021– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces today that it has completed the installation of automated mulberry processing equipment at its factory in Vietnam. This new equipment, which was announced earlier this month, is now fully operational and will play an important role in further expanding the Company’s silk production. 

As part of the Company’s roadmap to scale up silk production capacity at its production facility in Quang Nam, Vietnam, the introduction of automated equipment will be a key piece of meeting metric ton levels of recombinant spider silk production. The new equipment will automate the processing of fresh mulberry leaves, a key process input in manufacturing silk. With the ability to process 300kg/hr of mulberry leaves, the new equipment transitions Prodigy Textiles, the Company’s Vietnamese subsidiary, to the next expansion phase. In addition, this equipment eliminates a process bottleneck, while improving material handling consistency and quality. As the Company continues to expand production levels, this successful automation implementation will serve as a template for future equipment investments.

“This new equipment elevates our production operations to an entirely new level,” said COO Jon Rice. “While COVID-related restrictions in Vietnam continue to impact travel into and within the Country, our team did an excellent job of navigating those challenges. They successfully imported, installed, and have this equipment operating ahead of schedule. Today marks a very exciting moment in the modernization of our silk production operations and our efforts to fulfill the demand for a sustainable, eco-responsible super fiber, we call spider silk.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Transfers Onsite Testing and Screening of Transgenics Technology to its Prodigy subsidiary

Equipment transfer positions Prodigy to expedite production expansion and next-generation disease-resistant silkworms

ANN ARBOR, Mich., – June 7, 2021– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces the transfer of its onsite testing and screening of transgenics technology to Prodigy Textiles, the Company’s Vietnam based subsidiary.

The Company made the significant decision to transfer testing and screening technologies from its R&D headquarters in the US to its factory in Vietnam.  This testing equipment allows for precise screening and selection of the transgenics’ key genetic traits, which are currently conducted exclusively at the Company’s US headquarters.  Implementing this testing onsite eliminates the delay caused by transferring samples between the US and Vietnam and further strengthens the Company’s continued production operations against future challenges related to travel restrictions.  This new laboratory equipment is in addition to the recently reported production automation equipment that is being installed at the same facility.

This new testing capability will also support the Company’s development program to produce new disease-resistant strains of silkworms.  These new disease-resistant lines of silkworms are intended for licensing into the global market for mundane silks to combat pathogenic virus and fungi that account for the loss of approximately 20% of the typical global annual silk production.[1] 

“This move will dramatically increase our production efficiency and reduce costs of operations.  The labs at Prodigy will be fully equipped to conduct all material performance and genetic screening in real-time.  This technology transfer, coupled with the investment in equipment and staffing, will speed up our commercial production ramp-up while eliminating a log jam in operations and is expected to be online within 60 days.  Simultaneously, our US R&D team will be freed to focus its attention on bringing next-generation transgenics and materials to market,” said COO Jon Rice. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com


[1] Gani, Mudasir & Chouhan, Sahadev & Lal, Babu & Gupta, Rakesh & Rohela, Gulab & Neelaboina, Bharath & Saini, Pawan & Ghosh, M.. (2018). Bombyx mori nucleopolyhedrovirus (BmNPV): Its impact on silkworm rearing and management strategies. Biological Control. 31. 10.18311/jbc/2017/16269.

This entry was posted on by .

Kraig Biocraft Laboratories Strengthens Production Operations with New Automated Equipment

New Automated Equipment to expand and expedite Silk Processing  

ANN ARBOR, Mich., – June 1, 2021– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces considerable investments in strengthening its Vietnam based production operations.

Kraig Labs is in the process of receiving and installing equipment, which was purchased to speed up and expand silk production at the Company’s Prodigy Textiles facility. The new equipment will support the next phase of expansion, improving and automating a critical production step. 

In 2020, production in Vietnam was shut down due to mandatory governmental safety measures related to COVID-19.  Since restarting, the Company’s production facility has been in continuous operation with output limited by continued COVID-related restrictions on shipping and travel. The new equipment will support continued production, circumventing bottlenecks resulting from COVID-related restrictions.

“As we look to a post quarantine world, the Company is working aggressively to build resiliency into our production system, integrating core components of research and automation into our production factory,” said COO Jon Rice.  “COVID-19 resulted in a shutdown in 2020, and COVID’s recent spike in Vietnam has caused the Company to take these steps to facilitate our expansion.  We believe that these efforts to build resiliency will provide both long-term and immediate boosts to our operations.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Celebrates Arbor Day by Funding Planting of more than 100,000 Mulberry Trees

Kraig Labs honors its commitment to eco-responsible spider silk production with significant expansion of tree planting

ANN ARBOR, Mich., – April 30, 2021– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, honors Arbor Day by funding the planting of more than 100,000 mulberry trees.  While playing a vital role in purifying our air and stabilizing the soil, these trees also serve as a valuable, sustainable resource for the production of the Company’s proprietary spider silk technology.

The Company believes that in pledging to do what is right for the environment, it can strengthen its business and expand future opportunities.  Kraig Labs’ business model is built on the utilization of renewable and sustainable mulberry leaves for the production of recombinant spider silk.  Under the care of Prodigy Textiles, the Company’s Vietnamese subsidiary, these trees are already supporting production operations and will continue to play a significant role in the commercialization of Company’s recombinant spider silk technologies.

“Through thoughtful design of our production systems, with an eye towards energy efficiency, a reduction in inorganic materials, and a low carbon footprint, we created a system that is in line with long honored cultural traditions, where eco-responsibly is a valuable byproduct of doing what is best for our business and our shareholders,” said Jon Rice, COO.  “I am proud of the work our team has done to contribute to the more than two million acres of mulberry trees planted globally, as part of our efforts to bring materials of unparalleled performance to the textile markets.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories subsidiary, Spydasilk Enterprises, files for registration of multiple Spider Silk brand trademarks

Kings Group, Kraig’s joint venture partner, leads branding, with unique trademarks centered on spider silk

ANN ARBOR, Mich., – April 22, 2021– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that Spydasilk Enterprises Pte. Ltd. (“Spydasilk Enterprises”), the Company’s Singapore based joint venture, with M the Movement and Kings Golden Harvest Pte Ltd (collectively, “Kings Group”), has applied for its first four Spydasilk brand trademarks with the US Patent and Trademark office.

These first four trademarks include brand and product specific marking that Spydasilk Enterprises will use in the branding and marketing of its yarns, textiles, and finished garments.

“Our goal was to design the Spydasilk trademarks to be clean, distinctive, and powerful, able to stand alone or work in collaboration with co-branding opportunities with potential product partners.  I think that our design team delivered on all four of these criteria, creating a memorable brand with the unique inspired design,” said Walter Wee, CIO of Kings Group.

In addition to Spydasilk Enterprises developing a premium apparel, based on Kraig Labs’ spider silk technologies, Kraig Labs and Kings Group are simultaneously building other spider silk sales markets outside of apparel and textiles. With that in mind, the companies are working quickly to build Spydasilk Enterprises’ down channel distribution network.  These additional markets are expected to further expand the previously announced exclusive purchase and sales agreement, valued at up to US$40 million.

“SpydaSilk is obviously a unique enterprise, so we wanted to create trademarks that highlight the technology at the center of the brand. These trademarks provide distinctive styling that will help our customers easily identify Spydasilk’s product and the performance driven technologies at the heart of their design,” said Kim Thompson, Kraig Labs’ founder and CEO.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kings Group and M the Movement

Kings Group is headquartered in Singapore and established regional offices with multiple assets in Indonesia and Vietnam. Kings Group envisions itself to be a forerunner in International Marketing and Trading; bridging domestic businesses and projecting their products internationally.

For further information, please visit www.kings.com.sg

M the Movement is Kings Group’s premiere eco-friendly luxury streetwear line. Internationally recognized and loved by celebrities globally.

For more information, please visit www.mthemovement.com

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories and Kings Group form Spydasilk Enterprises Pte. Ltd., a Singapore based Joint Venture Company, for the marketing and sales of spider silk based products

Kraig’s joint venture with Kings is tied to the previously announced exclusive spider silk purchase and sales agreement valued at up to US$40 million

ANN ARBOR, Mich., – April 9, 2021– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that the Company, together with M the Movement, Kings Golden Harvest Pte Ltd (“Kings Group”), has established Spydasilk Enterprises Pte. Ltd. (“Spydasilk Enterprises”) as a Singapore based joint venture. 

This partnership represents the Company’s first vertically integrated sales channel.

Spydasilk Enterprises is developing a premium line of luxury streetwear based on Kraig Labs’ spider silk technologies with exclusive sales rights within the Association of Southeast Asian Nations (ASEAN) region. The move positions Kraig Labs and Kings Group to advance their partnership, which began with a previously announced exclusive purchase and sales agreement valued at up to US$40 million.

“Based on our initial efforts, there is a definite demand for spider silk technology and product developers are very excited about working with these super fibers,” said Walter Wee, CIO of Kings Group. “In addition to building up the Spydasilk brand, we must build Spydasilk’s vendor and customer bases. We are already having great success with clients that share our vision and passion for spider silk. We believe that their efforts will further broaden Spydasilk’s market opportunities in multiple industries asides from the fashion industry,” continued Wee.

The new joint venture company will commercialize Kraig Labs’ biodegradable and biocompatible ‘super fibers’, using a scalable and cost-effective spider silk production platform and patented spider silk gene sequences in silkworms.

“This new joint venture is the beginning of the fulfillment of my original vision for Kraig Labs, where we are able to vertically integrate and capture intermediate and end product margins.  Thanks to Walter and the Kings Group team, Spydasilk should hit the ground running. We have high expectations for the future of spider silk and Spydasilk Enterprises,” said Kim Thompson, Kraig Labs’ founder and CEO.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kings Group and M the Movement

Kings Group is headquartered in Singapore and established regional offices with multiple assets in Indonesia and Vietnam. Kings Group envisions itself to be a forerunner in International Marketing and Trading; bridging domestic businesses and projecting their products internationally.

For further information, please visit www.kings.com.sg

M the Movement is Kings Group’s premiere eco-friendly luxury streetwear line. Internationally recognized and loved by celebrities globally.

For more information, please visit www.mthemovement.com

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Secures $4 Million Dollars of Expansion Capital

ANN ARBOR, Mich., – March 26, 2021 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), announced today that it has secured $4 million dollars of expansion capital.  This financing significantly strengthens the Company’s balance sheet and supports its progress in the commercialization and sale of recombinant spider silk.  

“This is a major financial milestone for Kraig.  For many years we have operated on a shoestring budget, building a solid foundation with our spider silk production system.  We are now prepared to reap the rewards of that careful investment with opportunities to put this capital to work building materials, products and brands,” said CEO and Founder, Kim Thompson.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Except as required by law, the Company does not undertake any responsibility to revise or update any forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Announces Expanded Spider Silk Protection with Patent Granted in Vietnam

ANN ARBOR, Mich., – March 15, 2021– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that the University of Notre Dame has been granted a Vietnamese patent on spider silk technology developed pursuant to the collaborative research agreement with Kraig .  This patent plays a vital role in Kraig’s growing portfolio of spider silk Intellectual Property.  The Company’s recombinant spider silk production is headquartered in central Vietnam. 

Patent number 26612, titled “A Chimeric Spider Silk Polypeptide, Composite Fiber Comprising the Polypeptide and Method of Making a Chimeric Spider Fiber” was issued to the University of Notre Dame (UND) under the Company’s exclusive license agreement.  Under the terms of that agreement, the Company paid for the development of the technology and the costs of patents issued to UND in exchange for exclusive global licensing rights.  This patent provides protection for the Company’s proprietary recombinant spider silk through September of 2031.

With today’s announcement, the Company now expands protection for its spider silk technologies to include; Australia, South Korea, Canada, and Vietnam, with numerous other applications in other jurisdictions under review.

“Recognition by the Vietnamese government of our specialized spider silk technologies opens new doors and opportunities for production expansion within Vietnam.  Congratulations are in order for the researchers at the University of Notre Dame and Kraig for the breakthroughs that led to this patent.  I would also offer a special thanks to our counsel at Workmann Nydegger, who have done an excellent job of spearheading Kraig’s IP filings,” said COO Jon Rice.  “Our team at Kraig continues to prove that our vision for a cost-effective and environmentally responsible system for the commercialization of spider silk is now a reality.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.:

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include future sales of SpydaSilk™ and descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Increases Planned Production by Doubling Near Term Spider Silk Production Schedule

ANN ARBOR, Mich., – March 10, 2021– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that the Company has doubled its planned production volumes of its recombinant spider silk for the month of March.

Following the successful delivery of its first sample production run from its factory in Vietnam, the Company has further accelerated its expansion by doubling planned near-term silk output.  To support this expansion, the Company has outlined plans to more than double the staff at its Prodigy Textiles subsidiary.

The silk resulting from this month’s operations is expected to begin filling existing material requests and contract deliverables to M the Movement, PL Kings.  The Company is actively working now to develop the first line of apparel based on the unique properties of spider silk.

“Last month our team at Prodigy Textiles set the stage with the delivery of the first production samples of our recombinant spider silk.  This month that team is delivering on the promise of a cost-effective and commercially scalable spider silk production system,” said COO Jon Rice.  “I am very excited for the opportunities ahead for Kraig as we prepare to bring our spider silk to market.”

The Company seized the opportunity to expand near-term production of its eco-friendly spider silk when it was able to secure additional production inputs.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.:

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include the planned production of Spider Silk, future sales of SpydaSilk™ and descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Announces Spider Silk Patent Granted in Canada

ANN ARBOR, Mich., – March 2, 2021– Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that the University of Notre Dame has been granted a Canadian patent on spider silk technology developed pursuant to the collaborative research agreement with Kraig .  This patent further protects Kraig’s growing portfolio of spider silk Intellectual Property.

Patent number 2,812,791, titled “Chimeric Spider Silk and Uses Thereof” was issued to the University of Notre Dame (UND) under the Company’s exclusive license agreement.  Under the terms of that agreement, the Company paid for the development of the technology and the costs of patents issued to UND in exchange for exclusive global licensing rights.  This patent provides protection for the Company’s proprietary recombinant spider silk through September of 2031.

“Congratulations to both the researchers at the University of Notre Dame and Kraig’s science team.  Kraig Labs plans to continue building upon and protecting our position as a leading biomimicry company.  This patent is an important step on the Company’s path to remaining the premier technology and fiber supplier in the spider silk space,” said Jon Rice, the Company’s Chief Operations Officer. “We’ve created multiple strains of high-performance spider silk fibers that we are excited about.  Protecting our specialized materials in key end markets is a core component of our commercialization efforts.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.:

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include future sales of SpydaSilk™ and descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .